What i&i Prague does

i&i Prague, s.r.o. is a biotechnology incubator and venture builder founded in 2017 at the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences. The company operates a four-phase incubation program — Idea Evaluation, Pre-Incubation, Incubation (up to 36 months), and Post-Incubation (up to 10 years) — that guides academic researchers and early-stage biotech startups from concept through commercialization. Its service offering spans market analysis, industry feedback, initial funding, IP protection, team building (including CEO placement), and investor introductions across drug discovery, diagnostics, medical technologies, and life sciences. Headquartered in Prague with operations extending into Poland and Switzerland, i&i Prague has supported the creation of more than 15 spin-off companies originating from five countries and holds equity stakes in nine active portfolio companies.

The company's core operating assets are its incubation platform and the i&i Biotech Fund I (i&i Bio), a Luxembourg-domiciled venture capital fund established in 2021 in cooperation with the European Investment Fund. The fund manages over €45-53 million and invests across drug discovery, medical devices, diagnostics, and digital health, with an average ticket of ~€2M per project and exceptional cases up to €4.5M. Notable portfolio outcomes include Dracen Pharmaceuticals ($40.5M total raise led by Deerfield Management, DRP-104 in first-in-human trials), CasInvent Pharma (€1.6M Pre-Series A, €4M Eurostars grant), LAM-X (EIT Health MedTech Bootcamp 2020 winner, VerdiBlot product launched 2023), and two completed exits: DIANA Biotechnologies (February 2022, founder buyback) and Elphogene (February 2023, founder buyback). Direct revenue derives from incubation service fees, equity returns on portfolio exits, and venture fund management fees.

The business model combines professional services revenue (incubation agreements, consulting), carried interest and equity returns from portfolio holdings, and fund management economics through i&i Bio. Distribution is sales-led, driven by direct engagement with academic researchers at Czech and Polish institutions (IOCB Prague, Charles University, Masaryk University, Technical University of Liberec, Nencki Institute) and amplified through conference participation (BIO-Europe, Prague.bio, Hello Tomorrow). The team of under 10 employees operates from Prague with a lean organizational structure typical of academic spin-out incubators, with CEO David Stíbal and Managing Director Jiří Moos leading the platform.

Name

i&i Prague

Legal name

i&i Prague, s.r.o.

Website

https://iniprague.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

i&i Prague is a biotech incubator and venture builder founded in 2017 at IOCB Prague, operating a four-phase incubation program and the €45-53M i&i Biotech Fund I to commercialize academic research in drug discovery, diagnostics, and medical technologies for early-stage European startups.

Ownership category

akta.pro rank

Product category

Biotech Incubation and Venture Capital Services

NAICS

Other Scientific and Technical Consulting Services (54169), Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)

akta.pro secondary industries

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA), Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Biotech incubation services
• Venture capital fund
• Life sciences commercialization
• Technology transfer
• Early-stage biotech funding

Headquarters

HQ city

Praha

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Incubation Services: Provides expert consulting in scientific, legal, business, and other areas essential for the successful growth of new companies. Revenue generated through incubation fees and service contracts with early-stage biotech companies.
2. Equity Investment Returns: i&i Prague takes equity stakes in portfolio companies and generates returns through successful exits. Has invested approximately EUR 3 million in portfolio companies and helped raise approximately EUR 75 million from external investors.
3. Venture Capital Fund Management: Established i&i Biotech Fund in 2021 in cooperation with the European Investment Fund, managing over €47-53 million and investing in innovative European life sciences companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

i&i Prague is a biotech incubator and venture builder that provides a four-phase incubation program (Idea Evaluation, Pre-Incubation, Incubation up to 36 months, Post-Incubation up to 10 years) supporting early-stage biotech startups with market analysis, industry feedback, initial funding, and investor connections. The company also manages the i&i Biotech Fund I, a €47-53 million venture capital fund established in 2021 with the European Investment Fund, investing in innovative European life sciences companies in drug discovery, medical devices, diagnostics, and digital health. Core customers are academic researchers, biotech startups, and spin-offs in Central Europe and beyond.

Product overview

i&i Prague is a biotech incubator and venture builder, not a unified software product company. It operates a four-phase incubation program (Idea Evaluation, Pre-Incubation, Incubation up to 36 months, Post-Incubation up to 10 years) providing market analysis, initial funding, industry feedback, investor contacts, and expert consulting in scientific, legal, and business areas. The company also manages the i&i Biotech Fund (i&i Bio), a Luxembourg-based venture capital fund with over €47M under management investing in early-stage European life sciences companies. The portfolio spans drug discovery companies (CasInvent Pharma, Dracen Pharmaceuticals, Adalid Sciences, Deep MedChem, Pep-Therapy), diagnostics companies (Sophomer, Sampling Human, Promental Health), medical technology companies (LAM-X, Nanoflexion, RIOCATH, PerioTrap), and green chemistry (Sulfotools, Reecyclium). Three successful exits have been completed: DIANA Biotechnologies (2022), Elphogene (2023), and RIOCATH.

Differentiator

Problem solved

Functional benefit

Products and services

• Four-Phase Biotech Incubation Program Structured incubation program with four phases (Idea Evaluation, Pre-Incubation, Incubation up to 36 months, Post-Incubation up to 10 years) providing market analysis, initial funding, industry feedback, and investor connections for early-stage biotech startups and academic spin-offs.
• i&i Biotech Fund I (i&i Bio) Venture capital fund established in 2021 with the European Investment Fund, investing in innovative European life sciences companies focused on drug discovery, medical devices, diagnostics, and digital health. Manages over €47-53 million with plans to invest approximately €2 million average per project.

Quantifiable outcome

• 15+ spin-off companies supported from 5 countries
• +3 more outcomes

Named customers14 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

18 partnerships are on record, tiered core, flagship and minor.

• Institute of Organic Chemistry and Biochemistry (IOCB Prague)coreStrategic or Co-development Partneri&i Prague was founded in 2017 at the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. IOCB Tech is the parent technology transfer office. Partnership enables access to world-class research and pipeline of innovations for commercialization.
• Technical University of Liberec (TUL)flagshipStrategic or Co-development PartnerSigned incubation agreement in October 2025 to support Nanoflexion technology commercialization. TUL provides research and preclinical verification using their Nanospider® nanofiber production technology (170+ patents). Partnership involves Faculty of Textile Engineering and Institute for Nanomaterials, Advanced Technologies and Innovation.
• Faculty of Medicine of Charles University in PilsenflagshipStrategic or Co-development PartnerPartner in Nanoflexion incubation agreement providing preclinical and clinical testing expertise for nanofiber-based surgical patches to prevent postoperative complications in colorectal surgery.
• Johns Hopkins UniversityflagshipStrategic or Co-development PartnerInternational collaboration with Johns Hopkins Drug Discovery team for development of DRP-104 glutamine antagonist anticancer therapy. Dracen Pharmaceuticals originated from collaboration between IOCB Prague and Johns Hopkins University.
• Charles UniversitycoreStrategic or Co-development PartnerMajor academic partner with CUIP (Charles University Innovations Prague) for technology transfer. Partnership in LAM-X spin-off establishment and multiple other projects.
• Masaryk UniversitycoreStrategic or Co-development PartnerPartner in CasInvent Pharma spin-off from Faculty of Science. Technology Transfer Office collaboration for commercialization of CK1 inhibitors for leukemia treatment.
• IOCB TechcoreStrategic or Co-development PartnerParent technology transfer office and sister company. IOCB Tech identifies commercially interesting projects at IOCB, protects IP, and supports development. i&i Prague focuses on funding and incubation of early-stage projects.
• Institute of Macromolecular Chemistry (IMC)coreStrategic or Co-development PartnerAcademic partner for iBodies synthetic antibody technology and Sophomer polymer development. Joint technology development with IOCB and Charles University.
• Prague.bio ClustercoreStrategic or Co-development PartnerInternational biotech conference organized in cooperation with IOCB Tech and i&i Biotech Fund. Brings together academics, investors, and industry for biotech networking and deal flow.
• Hello Tomorrow EcosystemminorGTM or Marketing PartnerGlobal community boosting deep technology startups. i&i Prague joined as Ecosystem Partner to connect portfolio companies to global startup scene and increase visibility through Hello Tomorrow Global Challenge.
• XimbiominorChannel Partner/ Reseller/ DistributorTechnology transfer company within Cancer Research UK, world's largest non-profit focused on life-science research tools. Established cooperation for iBodies commercialization through global distribution network.
• Immunotech (Beckman Coulter)flagshipOEM/ Whitelabel/ Licensing PartnerLicensed iBodies® technology for measuring free testosterone in blood. Member of Beckman Coulter group using iBodies as component for new nonradioactive ELISA kit for clinical laboratory diagnostics.
• Genomac Research InstituteminorStrategic or Co-development PartnerElphogene was founded as spin-off from Genomac Research Institute for liquid biopsy technology development.
• CzechInvestminorStrategic or Co-development PartnerGovernment agency supporting foreign investment and business development. Partner in startup ecosystem and hackathon competitions.
• Czech Biotechnology Companies (BMS, Roche, Merck, Zentiva, SCT Bio)coreOthersMajor pharmaceutical and biotech companies listed as industry partners including Bristol-Myers Squibb, Roche, Merck, Zentiva, and SCT Bio for potential licensing, partnership, and investment opportunities.
• STAR Research and Innovation ClusterminorStrategic or Co-development PartnerOrganizer of Czech-Swiss Innovation Biotech Day 2025 at BIOCEV research centre in Prague.
• Nencki Institute (Poland)flagshipStrategic or Co-development PartnerCollaboration launched to develop innovative test for early diagnosis of Alzheimer's disease using novel microRNA biomarkers. Part of i&i Prague's expanded operations into Poland.
• Medical Innovation Institute (Poland)coreStrategic or Co-development PartnerPolish partner supporting cutting-edge scientific innovation in the region through joint incubation and investment activities.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BioInnovation Institute (BII): Danish biotech incubator/venture builder backed by the Novo Nordisk Foundation. Closest comparable: also a non-profit/Foundational biotech venture builder spinning out academic research into companies, with a multi-stage incubation program and an integrated venture arm.
• Apollo Therapeutics: UK-based translational medicine company builder jointly backed by AstraZeneca, GSK, and Johnson & Johnson. Directly comparable as a university spin-out commercialization platform with pharma partnership and integrated funding.
• BioGeneration Ventures (BGV): Dutch early-stage life sciences VC. Directly comparable as a European, early-stage biotech investor that originates and builds ventures from academic research with a hands-on incubation model.
• Oxford Science Innovations (OSI): University of Oxford-affiliated venture builder investing in deep-tech and life-sciences spinouts. Comparable in the academic-tech-transfer-backed venture-building model that i&i Prague applies to Czech research.
• Curie.Bio: US biotech founder-support platform that provides capital, lab space, and operational support to biotech startups. Comparable in providing hands-on incubation, operational support, and investor connections to academic founders.
• LabCentral: US non-profit biotech incubator providing lab space and shared resources to early-stage biotech startups. Comparable as a non-profit, founder-supporting biotech incubator, though i&i Prague's model is more venture-builder and less shared-lab.
• MBC BioLabs: US biotech incubator offering lab space and operational support. Comparable in the early-stage biotech incubation mission and founder-supporting model, although US-based and more lab-space focused.
• Cambridge Innovation Capital (CIC): UK venture firm investing in Cambridge University life-sciences and deep-tech spinouts. Comparable as a university-anchored venture builder with a similar focus on early-stage life sciences and a track record of academic commercialization.

Broad incumbents

• Forbion: Large Dutch life sciences VC (>€2B AUM). Comparable in life-sciences focus and European footprint but operates at much larger scale across multiple funds and stages, including growth equity.
• Evotec: German drug discovery/contract research company with venture-building activities (e.g., Evotec's BRIDGEs). Comparable in integrating drug-discovery platforms with venture creation, though at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/iniprague

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about i&i Prague